Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Pharmas Rush Into Vaccines: SK Chemicals Breaks Ground For Cell-culture Vaccines With Aid From Xcellerex

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's SK Chemicals joined the race with domestic manufacturers for cell-culture vaccine production, breaking ground June 15 for a cell-culture vaccine plant that will produce vaccines via a biomanufacturing platform from U.S.-based vaccine maker Xcellerex starting in the second half of 2014

You may also be interested in...



Mitsubishi Tanabe Pursues Next Generation Vaccines With Medicago, Tag-teams DPP-4 Market With Daiichi Sankyo

Mitsubishi Tanabe hopes to take on GSK’s Rotarix, the only rotavirus vaccine approved in Japan. And in a crowded DPP-4 field, Mitsubishi looks to double its sales efforts following a deal with Daiichi Sankyo.

Korea's Green Cross Strengthens Vaccine Supply Chain For Growing Export Demand

SEOUL - South Korea's leading vaccine producer Green Cross has opened and begun operation of a vaccine egg farm to build up a stable channel for the supply of flu vaccine eggs to the pharma's vaccine plant in Hwasoon, Southwest of Seoul. The company is preparing for increased domestic competition, but it also benefiting from a pickup in foreign demand

Korea's Green Cross Strengthens Vaccine Supply Chain For Growing Export Demand

SEOUL - South Korea's leading vaccine producer Green Cross has opened and begun operation of a vaccine egg farm to build up a stable channel for the supply of flu vaccine eggs to the pharma's vaccine plant in Hwasoon, Southwest of Seoul. The company is preparing for increased domestic competition, but it also benefiting from a pickup in foreign demand

Related Content

UsernamePublicRestriction

Register

SC078292

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel